Clinical Trial

Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1b, single-center, open-label study, evaluating efficacy and safety of RP1 for the treatment of resectable cutaneous Squamous Cell Carcinoma in up to 12 evaluable patients. In this study, patients will receive RP1 via direct intratumoral (IT) injection into superficial cutaneous solid tumors to assess the safety and tolerability as well efficacy of RP1 treatment. The primary efficacy population is up to 12 evaluable patients with resectable CSCC. The enrollment of patients with CSCC will determine study duration.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-04; most recent amendment 2025-12-29.
Status change: Recruiting → Active, Not Recruiting 2025-12-29
Status change: Not Yet Recruiting → Recruiting 2024-03-22
Trial Details
NCT Number NCT05858229
Lead Sponsor Sherrif Ibrahim
Conditions Squamous Cell Carcinoma, RP1
Enrollment 12 participants
Start Date 2023-06-16
Primary Completion 2025-12 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-31